Results 131 to 140 of about 396,344 (255)

STK Annual Meeting 2018

CHIMIA, 2018
Pierre Brodard
doaj   +1 more source

In vivo CAR-T engineering: insights from the 2025 ASH annual meeting. [PDF]

Exp Hematol Oncol
Asadi G, Rajabinejad M.
europepmc   +1 more source

Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients With Extrarenal Systemic Lupus Erythematosus—A Systematic Review and Meta‐Analysis

Arthritis Care &Research, EarlyView.
Objective Clinical response to mycophenolic acid (MPA) is highly heterogeneous; thus, therapeutic drug level monitoring (TDM) may help improve treatment efficacy. This systematic review and meta‐analysis examined therapeutic ranges for MPA levels associated with better outcomes and safety in patients with systemic lupus erythematosus (SLE ...
Zahraa Qamhieh, Dalia Sriwi, Callie Saric, Tripti Singh, Christie M. Bartels, Shivani Garg   +5 more
wiley   +1 more source

IFPOS 34th Annual Meeting

Journal of Children's Orthopaedics, 2015
doaj   +2 more sources

Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting. [PDF]

J Hematol Oncol
Sharma P, Jiang H, Liu D.
europepmc   +1 more source

Developing and Evaluating a Laboratory‐Based Frailty Index for the Prediction of Long‐Term Health Outcomes in Systemic Lupus Erythematosus

Arthritis Care &Research, EarlyView.
Objective We aimed to construct and evaluate the first laboratory‐based frailty index (FI‐Lab) for predicting adverse outcomes in systemic lupus erythematosus (SLE) and to compare its predictive ability to that of an existing clinical FI. Methods We used data from a single‐center prospective cohort of adult patients with SLE whose baseline visit ...
Grace Burns, Samuel D. Searle, Alexandra Legge   +2 more
wiley   +1 more source

Preclinical and clinical studies on CAR-NK cell therapy: latest update from 2025 ASH Annual Meeting. [PDF]

Exp Hematol Oncol
Luo H, Ding Y, Zhao X.
europepmc   +1 more source

Assessing the Sensitivity and the Clinical Impact of the 2023 American College of Rheumatology/EULAR Classification Criteria in Obstetric Antiphospholid Syndrome: Findings From a Multicenter Italian Cohort With a Long‐Term Follow‐Up

Arthritis Care &Research, EarlyView.
Objective The aim of this study was to evaluate the sensitivity of the 2023 American College of Rheumatology (ACR)/EULAR classification criteria for antiphospholipid syndrome (APS) in a real‐world cohort of women diagnosed with primary obstetric APS (oAPS) and to assess their ability to identify patients at risk of future pregnancy complications ...
Francesca Ruffilli, Cecilia Nalli, Francesca Crisafulli, Carlo Garaffoni, Marcello Govoni, Giulia Voltarel, Alba C. Pozzi, Beatrice Maranini, Ettore Silvagni, Alessandra Bortoluzzi, Angela Tincani   +10 more
wiley   +1 more source

Correction: ACNP 64^th Annual Meeting: Panels, Mini-Panels and Study Groups. [PDF]

Neuropsychopharmacology
europepmc   +1 more source

Assessment of Radiation Oncology Participation in Interdisciplinary Education at the American Society of Clinical Oncology Annual Meeting and Pathways to Expand Involvement. [PDF]

Adv Radiat Oncol
Sherwani ZK, Kumar R, Tabet A, Mattes MD.   +3 more
europepmc   +1 more source